Walleye Capital’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Walleye Capital’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-21,552	Closed	-$87.3K	–	6127
2023 Q4	$87.3K	Sell	21,552 -10,446	-33%	-$31.9K	﹤0.01%	4105
2023 Q3	$86.1K	Buy	+31,998	New	+$125K	﹤0.01%	4008
2023 Q2	–	Sell	-179,550	Closed	-$1.59M	–	5030
2023 Q1	$1.59M	Sell	179,550 -18,697	-9%	-$184K	0.02%	852
2022 Q4	$987K	Buy	198,247 +118,849	+150%	+$696K	0.02%	1007
2022 Q3	$461K	Buy	79,398 +47,679	+150%	+$337K	0.01%	1536
2022 Q2	$175K	Buy	+31,719	New	+$262K	﹤0.01%	1572

Walleye Capital's THRX Position: Q1 2024 in Review

Walleye Capital sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 21,552 shares — an estimated $87.3K sold.

Walleye Capital first reported a position in THRX in Q2 2022 and held it in 6 quarters. The position peaked at $1.59M in Q1 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

Walleye Capital reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Walleye Capital sold 21,552 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $87.3K.
Walleye Capital first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
Walleye Capital's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $1.59M in Q1 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.